- Home
- VTRS vs NIO Comparison
VTRS vs NIO Comparison
Compare VTRS & NIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTRS
- NIO
- Stock Information
- Founded
- VTRS 1961
- NIO 2014
- Country
- VTRS United States
- NIO China
- Employees
- VTRS N/A
- NIO N/A
- Industry
- VTRS Medicinal Chemicals and Botanical Products
- NIO Auto Manufacturing
- Sector
- VTRS Health Care
- NIO Consumer Discretionary
- Exchange
- VTRS Nasdaq
- NIO Nasdaq
- Market Cap
- VTRS 9.0B
- NIO 7.4B
- IPO Year
- VTRS N/A
- NIO 2018
- Fundamental
- Price
- VTRS $7.56
- NIO $3.52
- Analyst Decision
- VTRS Hold
- NIO Hold
- Analyst Count
- VTRS 4
- NIO 6
- Target Price
- VTRS $10.50
- NIO $5.05
- AVG Volume (30 Days)
- VTRS 17.3M
- NIO 61.9M
- Earning Date
- VTRS 05-08-2025
- NIO 06-05-2025
- Dividend Yield
- VTRS 6.50%
- NIO N/A
- EPS Growth
- VTRS N/A
- NIO N/A
- EPS
- VTRS N/A
- NIO N/A
- Revenue
- VTRS $14,739,300,000.00
- NIO $9,005,433,398.00
- Revenue This Year
- VTRS N/A
- NIO $37.33
- Revenue Next Year
- VTRS $1.20
- NIO $25.76
- P/E Ratio
- VTRS N/A
- NIO N/A
- Revenue Growth
- VTRS N/A
- NIO 18.18
- 52 Week Low
- VTRS $6.85
- NIO $3.02
- 52 Week High
- VTRS $13.55
- NIO $7.71
- Technical
- Relative Strength Index (RSI)
- VTRS 34.97
- NIO 39.90
- Support Level
- VTRS $7.34
- NIO $3.42
- Resistance Level
- VTRS $7.70
- NIO $3.71
- Average True Range (ATR)
- VTRS 0.43
- NIO 0.22
- MACD
- VTRS 0.01
- NIO 0.01
- Stochastic Oscillator
- VTRS 36.41
- NIO 51.02
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
About NIO NIO Inc. American depositary shares each representing one ordinary share
Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold around 222,000 EVs in 2024, accounting for about 2% of the China passenger new energy vehicle market.